Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Epoch Biosciences Inc.

Latest From Epoch Biosciences Inc.

Appointments: Synthorx, BTG, Pertinax, Realm, Breath, Aerie, iOnctura, Inflazome and NBE

The week's round-up includes a new CEO at Synthorx Inc., new sales executives at Aerie Pharmaceuticals and board appointments at BTG, Pertinax Pharma, Realm Therapeutics, Breath Therapeutics, iOnctura, NBE Therapeutics and Inflazome.

Executive Changes BioPharmaceutical

Are stars finally aligning for Takeda in India?

Metabolic Disorders Dermatology

Vitae partner Boehringer takes BACE inhibitor into the clinic

Boehringer Ingelheim initiated a Phase I clinical trial for the beta-secretase (BACE) inhibitor developed under a 2009 collaboration agreement with Vitae Pharmaceuticals, triggering a $14m milestone payment to the private biopharma company.

Metabolic Disorders Neurology

Merck gets BACE boost in Alzheimer's race

Merck & Co's MK-8931 has successfully cleared an early hurdle in the race to find a product that might treat Alzheimer's disease through beta secretase enzyme (BACE) inhibition. The firm reported positive Phase Ib results showing a quick, dose-dependent reduction in amyloid.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics